Rigel Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

FAIR VALUE (Tables)

FAIR VALUE (Tables)

6 Months Ended

Jun. 30, 2025

Schedule of financial assets measured at fair value on a recurring basis

The table below summarizes the fair value of our cash equivalents and short-term investments measured at fair value on a recurring basis, and are categorized based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of June 30, 2025
	Level 1		Level 2		Level 3		Total
Money market funds	$	17,166	$	—	$	—	$	17,166
US treasury bills		—		32,294		—		32,294
Government-sponsored enterprise securities		—		9,973		—		9,973
Corporate bonds and commercial paper		—		31,332		—		31,332
Total	$	17,166	$	73,599	$	—	$	90,765


	Assets at Fair Value as of December 31, 2024
	Level 1		Level 2		Level 3		Total
Money market funds	$	16,386	$	—	$	—	$	16,386
US treasury bills		—		7,263		—		7,263
Government-sponsored enterprise securities		—		23,177		—		23,177
Corporate bonds and commercial paper		—		10,360		—		10,360
Total	$	16,386	$	40,800	$	—	$	57,186